SG11201707148PA - Maytansinoid derivatives, conjugates thereof, and methods of use - Google Patents

Maytansinoid derivatives, conjugates thereof, and methods of use

Info

Publication number
SG11201707148PA
SG11201707148PA SG11201707148PA SG11201707148PA SG11201707148PA SG 11201707148P A SG11201707148P A SG 11201707148PA SG 11201707148P A SG11201707148P A SG 11201707148PA SG 11201707148P A SG11201707148P A SG 11201707148PA SG 11201707148P A SG11201707148P A SG 11201707148PA
Authority
SG
Singapore
Prior art keywords
conjugates
methods
maytansinoid derivatives
maytansinoid
derivatives
Prior art date
Application number
SG11201707148PA
Other languages
English (en)
Inventor
Thomas Nittoli
Thomas Markotan
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55650789&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201707148P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11201707148PA publication Critical patent/SG11201707148PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201707148PA 2015-03-27 2016-03-25 Maytansinoid derivatives, conjugates thereof, and methods of use SG11201707148PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562139044P 2015-03-27 2015-03-27
US201562252239P 2015-11-06 2015-11-06
PCT/US2016/024343 WO2016160615A1 (fr) 2015-03-27 2016-03-25 Dérivés de maytansinoïde, conjugués de ceux-ci, et procédés d'utilisation

Publications (1)

Publication Number Publication Date
SG11201707148PA true SG11201707148PA (en) 2017-10-30

Family

ID=55650789

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201707148PA SG11201707148PA (en) 2015-03-27 2016-03-25 Maytansinoid derivatives, conjugates thereof, and methods of use

Country Status (17)

Country Link
US (3) US20160375147A1 (fr)
EP (1) EP3273998B1 (fr)
JP (2) JP6948950B2 (fr)
KR (1) KR20170131587A (fr)
CN (2) CN115645543A (fr)
AU (1) AU2016243527B2 (fr)
BR (1) BR112017020149A8 (fr)
CA (1) CA2978340A1 (fr)
CL (1) CL2017002422A1 (fr)
CO (1) CO2017010890A2 (fr)
EA (1) EA034950B1 (fr)
IL (1) IL254267B (fr)
MX (2) MX2017012380A (fr)
PH (1) PH12017501780A1 (fr)
SG (1) SG11201707148PA (fr)
WO (1) WO2016160615A1 (fr)
ZA (1) ZA201706040B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015011348A (es) 2013-03-15 2016-01-15 Regeneron Pharma Moleculas biologicamente activas, conjugados de las mismas, y usos terapeuticos.
CN105530942B (zh) 2013-08-26 2019-10-11 瑞泽恩制药公司 一种包含大环内酯类非对映体的药物组合物、其制备方法和用途
EP3273998B1 (fr) * 2015-03-27 2019-09-04 Regeneron Pharmaceuticals, Inc. Dérivés de maytansinoïde, conjugués de ceux-ci, et procédés d'utilisation
EP3319994B1 (fr) 2015-07-06 2024-02-07 Regeneron Pharmaceuticals, Inc. Molécules multispécifiques de liaison à l'antigène et leurs utilisations
CN114478801A (zh) 2016-01-25 2022-05-13 里珍纳龙药品有限公司 美登素类化合物衍生物、其偶联物和使用方法
WO2017190079A1 (fr) 2016-04-28 2017-11-02 Regeneron Pharmaceuticals, Inc. Procédés de production de molécules multispécifiques se liant à l'antigène
MD3515487T2 (ro) 2016-09-23 2023-11-30 Regeneron Pharma Anticorpi bispecifici anti-MUC16-CD3 și conjugate anticorp anti-MUC16-medicament
CA3037732A1 (fr) 2016-09-23 2018-03-29 Regeneron Pharmaceuticals, Inc. Anticorps anti-steap2, conjugues anticorps-medicament, et molecules bispecifiques de liaison a l'antigene qui se lient a steap2 et cd3, et leurs utilisations
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
MX2019006131A (es) 2016-11-29 2019-08-21 Regeneron Pharma Metodos para tratar cancer de mama positivo para prlr.
CN110944718A (zh) 2017-05-18 2020-03-31 里珍纳龙药品有限公司 环糊精蛋白质药物偶联物
WO2019094395A2 (fr) 2017-11-07 2019-05-16 Regeneron Pharmaceuticals, Inc. Lieurs hydrophiles pour conjugués anticorps-médicament
IL305268A (en) * 2017-11-30 2023-10-01 Centurion Biopharma Corp Maytansinoid-based drug delivery systems
EP3788075A1 (fr) * 2018-04-30 2021-03-10 Regeneron Pharmaceuticals, Inc. Anticorps et molécules de liaison à l'antigène bispécifiques se liant à her2 et/ou aplp2, conjugués et utilisations associées
JP7477462B2 (ja) 2018-05-17 2024-05-01 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｃｄ６３抗体、コンジュゲート、及び、それらの使用
WO2020057543A1 (fr) * 2018-09-21 2020-03-26 中国人民解放军军事科学院军事医学研究院 Lieur à base d'aryle nitro, conjugué anticorps-médicament contenant un lieur et utilisation de lieur
WO2020172475A1 (fr) 2019-02-21 2020-08-27 Regeneron Pharmaceuticals, Inc. Méthodes de traitement du cancer oculaire à l'aide d'anticorps anti-met et de molécules bispécifiques de liaison à l'antigène qui se lient à met
CN114340684A (zh) 2019-09-16 2022-04-12 瑞泽恩制药公司 用于免疫pet成像的放射性标记的met结合蛋白
US11814428B2 (en) 2019-09-19 2023-11-14 Regeneron Pharmaceuticals, Inc. Anti-PTCRA antibody-drug conjugates and uses thereof
WO2021097220A1 (fr) 2019-11-15 2021-05-20 Seagen Inc. Méthodes de traitement du cancer du sein her2 positif avec du tucatinib en combinaison avec un conjugué médicament-anticorps anti-her2
CN113292574B (zh) * 2020-02-21 2022-05-03 四川大学 一类手性多环的托品烷化合物及其制备方法和用途
CA3166619A1 (fr) 2020-02-28 2021-09-02 Julian Andreev Molecules bispecifiques de liaison a l'antigene qui se lient a her2, et leurs procedes d'utilisation
WO2021211984A1 (fr) 2020-04-16 2021-10-21 Regeneron Pharmaceuticals, Inc. Procédés de conjugaison de diels-alder
CA3190569A1 (fr) 2020-10-22 2022-04-28 Christopher Daly Anticorps anti-fgfr2 et leurs methodes d'utilisation
WO2022103724A1 (fr) 2020-11-10 2022-05-19 Regeneron Pharmaceuticals, Inc. Conjugués d'anticorps au sélénium

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5566585A (en) * 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
TW200539855A (en) 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
BRPI0510883B8 (pt) 2004-06-01 2021-05-25 Genentech Inc composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
JP2008521828A (ja) 2004-11-29 2008-06-26 シアトル ジェネティックス， インコーポレイテッド 操作された抗体およびイムノコンジュゲート
PL1912677T3 (pl) 2005-06-20 2014-03-31 Psma Dev Company L L C Koniugaty przeciwciało PSMA-lek
AU2006262603B2 (en) 2005-06-20 2011-01-06 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CA2617953C (fr) 2005-08-09 2013-12-17 Millennium Pharmaceuticals, Inc. Procede d'acylation de maytansinol a l'aide d'aminoacides chiraux
AU2006330562B2 (en) 2005-12-22 2013-05-02 Baxter Healthcare S.A. Improved monocyte activation test better able to detect non-endotoxin pyrogenic contaminants in medical products
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
WO2008122039A2 (fr) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Molécules d'anticorps hybrides médiées par la sélénocystéine
EP2167963B1 (fr) 2007-05-23 2019-04-17 Ventana Medical Systems, Inc. Supports polymères pour immunohistochimie et hybridation in situ
BRPI0911442A2 (pt) 2008-04-30 2019-03-12 Immunogen, Inc. conjugados potentes e ligantes hidrofílicos
AU2009275358C1 (en) 2008-07-21 2015-09-24 Polytherics Limited Novel reagents and method for conjugating biological molecules
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
DK2889624T3 (en) 2009-08-10 2018-12-10 Ucl Business Plc Reversible covalent bonding of functional molecules
US20130028917A1 (en) 2010-04-15 2013-01-31 Spirogen Developments Sàrl Pyrrolobenzodiazepines and conjugates thereof
WO2012005982A2 (fr) 2010-07-06 2012-01-12 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Rapporteur pour une terminaison par la arn polymérase ii
NZ707327A (en) 2010-08-02 2017-01-27 Regeneron Pharma Mice that make binding proteins comprising vl domains
EP2714685B1 (fr) 2011-05-27 2016-10-19 Ambrx, Inc. Compositions contenant des dérivés de dolastatine liés à des acides aminés non naturel
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
WO2012177837A2 (fr) * 2011-06-21 2012-12-27 Immunogen, Inc. Nouveaux dérivés de maytansinoïde comprenant un lieur peptidique et conjugués correspondants
KR101891859B1 (ko) 2011-10-14 2018-08-24 메디뮨 리미티드 피롤로벤조디아제핀
WO2013053872A1 (fr) 2011-10-14 2013-04-18 Spirogen Sàrl Procédé de synthèse et intermédiaires pouvant servir à préparer des pyrrolobenzodiazépines
CN103997893B (zh) 2011-10-14 2019-04-12 西雅图基因公司 吡咯并苯并二氮杂卓和靶向结合物
WO2013055990A1 (fr) 2011-10-14 2013-04-18 Seattle Genetics, Inc. Pyrrolobenzodiazépines et conjugués ciblés
WO2013068874A1 (fr) 2011-11-11 2013-05-16 Pfizer Inc. Conjugués anticorps-médicament
IN2014CN04961A (fr) 2011-12-05 2015-09-18 Igenica Biotherapeutics Inc
CN110201186A (zh) 2012-10-23 2019-09-06 西纳福克斯股份有限公司 经修饰的抗体、抗体-缀合物及其制备方法
ES2701076T3 (es) * 2012-11-24 2019-02-20 Hangzhou Dac Biotech Co Ltd Enlazadores hidrofílicos y sus usos para la conjugación de fármacos a las moléculas que se unen a las células
MX2015011348A (es) * 2013-03-15 2016-01-15 Regeneron Pharma Moleculas biologicamente activas, conjugados de las mismas, y usos terapeuticos.
WO2014197854A1 (fr) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Nouveaux lieurs pour conjugués anticorps-médicament et composés connexes, compositions, et procédés d'utilisation
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
CN105530942B (zh) * 2013-08-26 2019-10-11 瑞泽恩制药公司 一种包含大环内酯类非对映体的药物组合物、其制备方法和用途
EP3273998B1 (fr) * 2015-03-27 2019-09-04 Regeneron Pharmaceuticals, Inc. Dérivés de maytansinoïde, conjugués de ceux-ci, et procédés d'utilisation

Also Published As

Publication number Publication date
WO2016160615A1 (fr) 2016-10-06
BR112017020149A2 (pt) 2018-09-11
EP3273998B1 (fr) 2019-09-04
CA2978340A1 (fr) 2016-10-06
JP2018516851A (ja) 2018-06-28
EA034950B1 (ru) 2020-04-09
PH12017501780A1 (en) 2018-04-30
KR20170131587A (ko) 2017-11-29
JP6948950B2 (ja) 2021-10-13
CO2017010890A2 (es) 2020-04-13
CL2017002422A1 (es) 2018-03-16
US20220259225A1 (en) 2022-08-18
CN107995912A (zh) 2018-05-04
JP2021113191A (ja) 2021-08-05
IL254267A (en) 2018-06-28
AU2016243527B2 (en) 2021-04-29
EP3273998A1 (fr) 2018-01-31
ZA201706040B (en) 2020-05-27
IL254267B (en) 2021-03-25
BR112017020149A8 (pt) 2023-05-02
CN115645543A (zh) 2023-01-31
US20200385402A1 (en) 2020-12-10
MX2017012380A (es) 2018-04-11
EA201700464A1 (ru) 2018-11-30
US20160375147A1 (en) 2016-12-29
MX2021008101A (es) 2021-08-05
AU2016243527A1 (en) 2017-09-21

Similar Documents

Publication Publication Date Title
HK1257219A1 (zh) 美登素類化合物衍生物、其偶聯物和使用方法
ZA201706040B (en) Maytansinoid derivatives, conjugates thereof, and methods of use
IL261428A (en) Antibody-drug conjugates based on eribulin and methods of use
HK1231367A1 (zh) 抗體藥物偶聯物、試劑和製備方法及其治療用途
IL261493A (en) Napi2b-targeted antibody conjugates - drug and methods of using them
IL248961A0 (en) Oristatin histories and their conjugations
EP3204018A4 (fr) Utilisation néoadjuvante de conjugués anticorps-médicaments
EP3151830A4 (fr) Conjugués anticorps anti-her2-maytansine et méthodes d'utilisation de ceux-ci
EP3138568A4 (fr) Nouveau conjugué anticorps-médicament stable, procédé pour le préparer, et son utilisation
EP3154972A4 (fr) Dérivés d'azamophinan et leur utilisation
EP3154971A4 (fr) Dérivés hétérocycliques de morphinan et leur utilisation
EP3386986A4 (fr) Conjugués porphyrine d'or-peg et procédés d'utilisation
EP3283493A4 (fr) Conjugués de texaphyrine-phospholipide et leurs procédés de préparation
IL275190A (en) Anti-CD22 antibody-maytensin conjugates, combinations and methods of using them
IL249394A0 (en) Anti-cd22 drug-antibody conjugates and methods of using them
HK1258409A1 (zh) 抗cd22抗體-美登木素綴合物及其使用方法
HK1256368A1 (zh) 加利車黴素-抗體-藥物綴合物和使用方法
IL261643B (en) Piperidine derivatives, their preparation and use
PT3544637T (pt) Conjugados omv-antigénio nativos e sua utilização
PL3386988T3 (pl) Nowe pochodne dihydropiranopirymidynonu i ich zastosowanie
PL3166945T3 (pl) Nowe pochodne triazolopirymidynonu lub triazolopirydynonu i ich zastosowanie
HRP20182167T1 (hr) Derivati benzilhidroksida, njihova priprava i njihova terapeutska uporaba
GB201619946D0 (en) Conjugated immunogenic derivatives and use thereof
GB201615010D0 (en) Delayed-gelling, inhibited starches and methods of using them